www.mediafax.ro/externe/medicamentele-ar-putea-fi-

Artificial intelligence is emerging as a new channel for pharmaceutical promotion to doctors in China, as companies seek to adapt to stricter anti-corruption regulations. Pharmaceutical firms are exploring ways to pay for the inclusion of their studies in AI-generated responses from medical assistants. Alibaba Health is considering a commercial model for its Hydrion app, which could display promoted research alongside AI answers. A survey indicates that 93% of Chinese doctors now use AI tools, reflecting a significant increase. Other companies are also integrating AI assistants into their platforms to enhance medical training and research visibility. The digital health marketing sector in China is projected to grow significantly by 2030, attracting interest from both local and international pharmaceutical companies.